RxDoctor Payments Data

Michael Colotta

Family · Henderson, TXNPI 1477824340

Payments from drug & device makers

$9,145in general payments, 2019–2025

Across 569 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Amgen$689
  • Bayer$600
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$9,145100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,145 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$57,145
Medicare patients
248
Services billed
1,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide64$87,792
OzempicSemaglutide62$76,780
TrulicityDulaglutide48$58,583
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$48,067
FarxigaDapagliflozin Propanediol31$30,756
EliquisApixaban29$28,492
Stiolto RespimatTiotropium Br/Olodaterol Hcl43$25,855
XareltoRivaroxaban25$24,762
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$18,039
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$15,581
Janumet XrSitagliptin Phos/Metformin Hcl15$14,392
Breo ElliptaFluticasone/Vilanterol31$12,778
Acetaminophen-CodeineAcetaminophen With Codeine143$3,335
Testosterone Cypionate54$3,163
Rosuvastatin Calcium312$2,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,257$146,375112 claims
Novo NordiskOzempic$1,160$76,78062 claims
GSKTrelegy Ellipta, Breo Ellipta$223$60,84579 claims
AstraZenecaFarxiga$1,147$30,75631 claims
PfizerEliquis$280$28,49229 claims
Boehringer IngelheimStiolto Respimat$353$25,85543 claims
Johnson & JohnsonXarelto$264$24,76225 claims
MerckJanumet Xr$99$14,39215 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$2,169217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Henderson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →